Published in J Acquir Immune Defic Syndr on January 01, 2011
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Diagnostic point-of-care tests in resource-limited settings. Lancet Infect Dis (2013) 3.56
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis (2012) 1.90
Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. J Infect Dis (2012) 1.82
The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis (2012) 1.80
HIV self-testing and the missing linkage. PLoS Med (2011) 1.57
Transitioning HIV care and treatment programs in southern Africa to full local management. AIDS (2012) 1.47
Suboptimal patterns of provider initiated HIV testing and counselling, antiretroviral therapy eligibility assessment and referral in primary health clinic attendees in Blantyre, Malawi. Trop Med Int Health (2012) 1.41
High prevalence of self-reported undiagnosed HIV despite high coverage of HIV testing: a cross-sectional population based sero-survey in South Africa. PLoS One (2011) 1.33
Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr (2013) 1.12
Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS One (2014) 1.07
Behavioral and biomedical combination strategies for HIV prevention. Cold Spring Harb Perspect Med (2012) 1.03
Balancing efficiency, equity and feasibility of HIV treatment in South Africa - development of programmatic guidance. Cost Eff Resour Alloc (2013) 1.02
HIV, tuberculosis, and noncommunicable diseases: what is known about the costs, effects, and cost-effectiveness of integrated care? J Acquir Immune Defic Syndr (2014) 1.01
The survival benefits of antiretroviral therapy in South Africa. J Infect Dis (2013) 0.98
Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. EBioMedicine (2015) 0.92
Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. Nat Commun (2014) 0.91
Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. PLoS One (2013) 0.91
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health (2013) 0.87
Implementing a provider-initiated testing and counselling (PITC) intervention in Cape town, South Africa: a process evaluation using the normalisation process model. Implement Sci (2013) 0.87
Modelling the potential population impact and cost-effectiveness of self-testing for HIV: evaluation of data requirements. AIDS Behav (2014) 0.87
Heterogeneous HIV testing preferences in an urban setting in Tanzania: results from a discrete choice experiment. PLoS One (2014) 0.85
A cost-effectiveness analysis of alternative HIV retesting strategies in sub-saharan Africa. J Acquir Immune Defic Syndr (2011) 0.85
A qualitative analysis of the barriers and facilitators of HIV counselling and testing perceived by adolescents in South Africa. BMC Health Serv Res (2015) 0.83
Opportunities for strengthening provider-initiated testing and counselling for HIV in Namibia. AIDS Care (2015) 0.82
Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis. Lancet HIV (2016) 0.80
Development, calibration and performance of an HIV transmission model incorporating natural history and behavioral patterns: application in South Africa. PLoS One (2014) 0.80
A comparison of linkage to HIV care after provider-initiated HIV testing and counselling (PITC) versus voluntary HIV counselling and testing (VCT) for patients with sexually transmitted infections in Cape Town, South Africa. BMC Health Serv Res (2014) 0.78
Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. Am J Epidemiol (2016) 0.78
Incidence of TB and HIV in prospectively followed household contacts of TB index patients in South Africa. PLoS One (2014) 0.77
The effects of HIV self-testing on the uptake of HIV testing and linkage to antiretroviral treatment among adults in Africa: a systematic review protocol. Syst Rev (2016) 0.76
Routine HIV screening in Portugal: clinical impact and cost-effectiveness. PLoS One (2013) 0.75
Operations research in global health: a scoping review with a focus on the themes of health equity and impact. Health Res Policy Syst (2017) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS (2008) 9.10
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet (1999) 6.40
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health (2003) 6.02
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990--2005. AIDS Behav (2007) 4.61
Gains in life expectancy from medical interventions--standardizing data on outcomes. N Engl J Med (1998) 4.47
The costs and effectiveness of four HIV counseling and testing strategies in Uganda. AIDS (2009) 4.45
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
A randomized trial on acceptability of voluntary HIV counselling and testing. Trop Med Int Health (2004) 4.13
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One (2010) 3.38
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr (2007) 2.71
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital. J Acquir Immune Defic Syndr (2006) 2.67
Use of pharmacoeconomics information--report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health (2003) 2.61
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr (2009) 2.24
"I have an evil child at my house": stigma and HIV/AIDS management in a South African community. Am J Public Health (2005) 2.24
The feasibility, demand, and effect of integrating primary care services with HIV voluntary counseling and testing: evaluation of a 15-year experience in Haiti, 1985-2000. J Acquir Immune Defic Syndr (2003) 2.18
The stigma of being HIV-positive in Africa. PLoS Med (2005) 1.98
Two and a half years of routine HIV testing in Botswana. J Acquir Immune Defic Syndr (2007) 1.95
Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis. Int J STD AIDS (2008) 1.45
The cost-effectiveness of expanded testing for primary HIV infection. Ann Fam Med (2005) 1.42
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa. Bull World Health Organ (2010) 1.12
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med (2002) 1.11
Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS (2007) 1.02
Incubation time of acute human immunodeficiency virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis (2000) 1.01
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29
Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20
Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS (2009) 4.07
Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis (2010) 3.96
Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should. AIDS (2010) 3.93
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis (2008) 3.92
Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS (2009) 3.91
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis (2009) 3.89
Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Arch Intern Med (2009) 3.84
Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis (2009) 3.77
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther (2007) 3.60
Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med (2008) 3.56
Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One (2010) 3.48
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. J Bone Joint Surg Am (2003) 3.33
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther (2007) 3.27
Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin Exp Res (2004) 3.24
Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS (2005) 3.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med (2006) 3.09
Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Med (2011) 3.08
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med (2005) 3.01
Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health (2009) 2.99
Association of hospital and surgeon volume of total hip replacement with functional status and satisfaction three years following surgery. Arthritis Rheum (2003) 2.98
Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J (2009) 2.97
Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS (2008) 2.96
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92
Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr (2007) 2.91
Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS (2010) 2.90
When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (2006) 2.85
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa. PLoS Med (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79